IMDX INSIGHT MO DIAG
$1.86
INSIGHT MO DIAG Q3 F2026 Earnings Call Transcript
AI Conference Call Analysis
Sign in or subscribe to read.Gabby
Call Moderator
Welcome everyone and thank you for joining us to discuss Insight Molecular Diagnostics third quarter 2026 results. If you have not seen today's shareholder letter, please visit our shareholder letter, please visit imdx.inc.com for today's letter. Today's prepared remarks build upon the information already shared in this robust letter. Joining us today are Insight Molecular Diagnostics President and CEO Josh Riggs, Chief Science Officer Ekke Schutz, and CFO Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Before turning the call over to Josh Riggs, I'd like to review our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company's SAC filings, including the company's most recent form 10-K and subsequent forms 10-Q, which identify risks and uncertainties that may cause future actual results or events to differ materially. Please note that the forward-looking statements made during today's call speak only to the day that they are made, and Insight Molecular Diagnostics undertakes no obligation to update them. And with that, I would like to now turn the call over to Josh Riggs.
Josh Riggs
President and CEO
Thanks, Gabby. Good afternoon, everybody, and thanks for joining us. Today, I will focus on two main topics, start of U.S. revenue from graph to shore, and what we believe will be the final steps related to our FDA submission. We've made investment into two areas to drive pre-DX launch revenue. Admittedly, this revenue stream has taken a little bit longer than we had hoped to get started, but it seems like it is finally ready to begin, namely from the Galactic Registry and also the Betasite program, which I will describe in a moment. Before I get to that, I'd like to mention our new head of commercial, Donnie Purto. Mr. Purto is an accomplished sales leader with more than 20 years of experience building and leading high-performing sales organizations across diagnostics, life sciences, and healthcare. During a decade at Natera, he had success in leadership roles spanning sales, training, oncology, transplant, and women's health. He managed new product launches as well as hundreds of millions of dollars in revenue in highly competitive markets. His experience makes him a great fit as we transition out of the development stage towards being fully commercial. We're counting on his leadership to make Graftassure the leading product in transplant management. On that, I'm pleased to announce we've officially started enrolling patients in our galactic registry. Big congratulations to the UCLA team for being the first to enroll. They've been a foundational site for the validation of DDC-FDNA broadly, and we are glad to have them on board as we build the next generation of clinical utility. As a reminder, Galactic aims to show the power of having a positive predictive value north of 80%. Contrast that with current assays clocking at around 50%, which is basically just a coin flip. The expectation is that we'll see a higher on-target rate for biopsies. It looks like we're going to have five or so sites enrolling by the end of the year, with more in the hopper for Q1. Enrollment in the galactic study begins a mostly predictable revenue stream, and importantly, it means that the clinical community will gain experience using our Graft Assure tests. Shifting over, for about a year and a half, we've been supporting beta sites across the United States. The goal was to get centers familiar and comfortable with Graft Assure technology. We've seen a couple head-to-heads come out demonstrating equivalency to legacy tests. This is great for building clinical confidence. And just recently at ASHI, one site showed a turnaround time of just six and a half hours. That's a significant improvement over the several days it takes to get a send-out test back. Quickly, just in case anyone needs it, ASHI is an annual conference where transplant lab leaders meet to learn about new technology and best practices. Perhaps the most exciting news coming out of that conference is how close transplant centers are to launching in-house GDC-FDNA testing services here in the United States. It's clear to us that leading labs are no longer intimidated by the idea of bringing testing in-house. A handful of hospital laboratories have completed both analytical and clinical validation and are moving on towards reimbursement. By our count, centers representing a little north of 1 in 20 U.S. kidney transplants have indicated that they are committed to in-house testing and lining up to launch in 2027. I expect that this will be a watershed moment in the transition from centralized to local care. The support of ASHI broadly has been great. They continue to make progress on establishing proficiency guidelines, which lays the groundwork for the broad adoption of DDC-FDNA at HLA labs across the United States. Shifting over to the FDA. In late July, the FDA completed the first phase of its substantive review of Graft Assured DX and requested additional information. Just comment for a de novo submission such as ours. In late September, we met with the FDA to discuss our approach to addressing the additional information request. Known as an SIR meeting, this is a de-risking step to help make sure we have good alignment on expectations. The agency has provided both verbal and written feedback to help guide our next data package. We are busy finishing up the extra homework they gave us on our way to a final submission. We have two external processes that factor into the timing for our response. The first is an independent study to further demonstrate the accuracy and consistency of our test results. This will bolster our internally generated data. And the second is an additional review of biopsy slides for which we have secured two well-known expert pathologists to establish the diagnoses against which our test results will be evaluated. We currently expect both processes to be completed before the end of the year and to submit our complete response before the January 21-27 deadline that we have. The FDA has a targeted review timeline of 150 days for Class 2 de novo submissions. Since we received the additional information request in late July, the review clock has been paused. We estimate that approximately half of the review days remain and the clock will restart once we submit. One additional note before I hand the call over to Andrea. We have added graft-assured urine screening for T-cell mediated rejection into our pipeline. Missing early TCMR has been one of the biggest drawbacks of today's blood-based test. We believe that we are the first company to demonstrate the ability to detect early TCMR in urine using a donor-derived cell-free DNA test. We can see a future where docs will order both blood and urine together in the first three years to rule out both main types of rejection, AVMR and TCMR. We believe that this has the opportunity to drive significant growth in demand. This will come alongside our expansion to heart testing in transplant patients in 2027. Now I'll hand over to Andrea to take us through the financials.
Andrea James
Chief Financial Officer
Thanks, Josh. Hi, everyone. Okay, so earlier today, we published our robust shareholder letter, and that allows me to keep my prepared remarks relatively short. That was filed as an AK right after the close. It took us a minute to get it up online, but hopefully you all had a chance to read it. Regarding our third quarter performance, I want to point out simply that our operating expenses and free cash flow trended in the right direction. So operating expenses peaked in Q4 2025 as we incurred significant expenses associated with our FDA program. As we alluded to last quarter, we believe that cash burn had bottomed in Q2 of 2026, so the most recent quarter, behind us, and as we work through some of those payments that were associated with our Q4 gap expenses. That OPEX growth that you saw go through the P&L over the last several quarters was driven largely by our FDA program. So OPEX peaked in Q4 2025 when R&D expenses reached $5.8 million, and that's above $2 million above the prior quarter, Q3, and it was driven by lab supplies, consulting, and FDA trial site costs. So R&D backed down to $3.8 million in the third quarter, and that still includes the remaining work to advance the graft-assured DX toward authorization. You'll notice in the third quarter that operating expenses, less the non-cash items, were flat with Q3 a year ago. So you can really see those FDA program expenses winding down. And as the FDA review concludes, the R&D focus shifts from securing authorization to building out the graft-to-short platform by expanding the menu, which Josh had talked about, and the evidence base so that each transplant center can do more with our technology. Our target is for future FDA programs to be sustained by the gross profit from our kidney transplant assay. Before we go to questions, I thought I'd share what brings me excitement about our trajectory and why, since becoming CFO, I have invested in the company personally, both through capital raises as well as via open market buying. IMDx has many of the hallmarks of companies that enjoy the kind of growth that comes from disrupting a market. The concept of turning a molecular lab test into a kit is a good idea, and you need three ingredients for this idea to be successful. You need high clinical demand, meaning will doctors order the test? You need strong reimbursement, meaning can we get paid? And you need the product to be IP protected, meaning we have a right to sell it with a sustainable competitive advantage. IMDx has all three. For high clinical demand, donor-derived cell-free DNA tests are already ordered in the hundreds of thousands of times per year, every year by clinicians. and these same clinicians who order these tests are telling us that they want to do their own testing. As a matter of fact, Josh is sitting with a lot of these potential future customers right now. For reimbursement, we've had Medicare Moldex reimbursement since August 2023 on our Tennessee lab developed test and FDA authorization would allow us to port this reimbursement to our customer labs. And finally, our proprietary digital PCR-based assay is IP protected and we expect to continue to grow our patent portfolio. Thank you so much for joining us. Okay, Gabby, now we can take questions. And I saw some of the hands come up while I was speaking.
Gabby
Call Moderator
Eric, can you put us into gallery mode, please? All right, we'll start with Alex Norwood from Lucid.
Alex Norwood
Analyst, Lucid
All right. Hey, good afternoon, everyone. Hopefully you can hear and see me. Thanks for taking the time. Appreciate it. So the release says basically the release says FDA's preliminary view is that the submitted clinical data does not yet support the proposed intended use. What is can you just expand on really what that means? Like what are the FDA ultimately is pushing back around?
Josh Riggs
President and CEO
Yeah, I would say there was the size. So we had only submitted about 75 samples. They wanted more subgroup analysis, which we'll be able to do with the larger sample set that we have available to us now. And then there's the additional studies that they were asking for, one of which we referenced here, which is the additional accuracy studies that were to be performed outside. and I think that all rolls together. I think it's just kind of blanket language that says they weren't completely satisfied and they wanted to see a little bit more information from us.
Alex Norwood
Analyst, Lucid
Sure. I mean, the company has tons of samples, tons of data, tons of publications that I think you can rely upon. Do you need to go back and do a bigger, broader study? Based on the feedback, do you really think you could put everything together that you have and get it through the FDA when you go back to them in January?
Josh Riggs
President and CEO
Yeah, I think we're in great shape. We've tripled the amount of sample that's available to us since we first started. And so we're in much better shape to answer some of the more detailed questions. And unfortunately, the FDA doesn't let you point to your 10 years of history as an LDT. They want fresh samples that came out of the FDA perspective study.
Alex Norwood
Analyst, Lucid
Got it. Okay. And then maybe just one more kind of follow-up to all this. So you respond to the FDA end of January, let's say. Walk me through the timeline a little bit. So we got half the review clock remaining. I'm thinking, you know, launch is going to be looking like a second half of 27. What can you do really between now and then to kind of seed the market, you know, get things established at the transplant centers, get reimbursement established, etc.? ?
Josh Riggs
President and CEO
As far as our understanding goes, there's no mechanism to stop the clock again. And so once we submit the package, we're really on this kind of like, call it 75-day window. Does that mean that they're going to be completely done in 75 days? No. I mean, they have the opportunity to extend beyond that, but we expect that they're going to hold close to that.
Alex Norwood
Analyst, Lucid
Okay. And then just timeline on launch, reimbursement, and kind of seeding the market?
Josh Riggs
President and CEO
Yeah, so the launch would happen, I'd say, right after authorization. The only difference between the RUO version of the test and the IVD version of the test is a sticker. And so we're already manufacturing the exact same product that would go into the IVD box. Seeding the market has been happening through the beta site program, which we discussed. and then also through the FDA program. Every one of the centers that you see listed on our fdatrials.gov site has our instrument in-house. So all of the data was generated locally. Every one of these centers is familiar with our workflow, has been trained on it and ready to adopt.
Alex Norwood
Analyst, Lucid
Okay. All right. Well, good stuff. Thank you for the time. Appreciate it. Thanks, Alex.
Gabby
Call Moderator
Thanks, Alex. Mark Massaro from BTIG.
Mark Massaro
Analyst, BTIG
Hey, guys. Thanks for taking my questions. How's it going? Yeah, so I wanted to ask, was there any, had you submitted any biopsy slides in the first submission or is that something that came perhaps as a surprise to you?
Josh Riggs
President and CEO
Well, we tried to do just the local pathologist and the FDA really didn't like that. They said, we want to see a three-part review. So you have a national reviewer and then you have a tiebreaker that sits on top of it. One of the long pulls for us was getting all of that organized, getting all the slides up into a digital database. That's all going now, so they're all being reviewed. But that was something that they clearly were not excited about in our original submission.
Mark Massaro
Analyst, BTIG
Okay. I just wanted to clarify the significance of the January 21st deadline. Why is that the right date? Maybe that's day 180, perhaps? Correct me if I'm wrong. But the other thing is, in the event you need more time, I know you think you'll hit it, but if you did need more time, is there a process in place that would allow you more time?
Josh Riggs
President and CEO
Yeah, you'd have to resubmit at that point. It basically kills the submission and you're starting back over, so you're restarting the 150-day clock.
Mark Massaro
Analyst, BTIG
Gotcha. And just for clarification, you're feeling pretty confident that you'll hit these two additional processes by, is it year-end 2026? So you're giving yourself like a three-week... Yeah, that's exactly right. Okay. Okay. Last question for me. As we think about the market for your LDT, and recognizing that Graphiture DX will be the core product going forward, how do we think about you selling those two in tandem? I would expect the kit would probably be Exhibit A for quite some time, but how do you think about offering both of them?
Josh Riggs
President and CEO
Yeah, I would say, you know, with the registry, those samples will come to us until we get to phase two. And so as we were working with these centers, we negotiated that there would be a phase one and phase two in the registry. And so phase two is they start running it themselves. And so they stopped sending samples to us like, We have Mike Mattson from Needham.
Mike Matson
Analyst, Needham
Yeah, thanks for taking my questions. I guess, you know, just want to ask one about the heart trials. So just given the kind of extended timing on the de novo for kidney and the fact that you want to kind of fund, you know, the other trials with the gross profits from, you know, kidney, does that mean that's going to get pushed out of a few, you know, a few quarters as well?
Josh Riggs
President and CEO
Yeah, I'd say, you know, we had a KOL call maybe two months ago with Loyola where they were talking about, you know, they wanted to start sending us samples and doing a head-to-head. And that's, I think, the advantage of going into heart as opposed to kidney surgery. We're in kidney, we were de novo, like we're the first one to go through the FDA. It's why we're facing so much scrutiny on the process. In heart, there is a predicate device. And so all I have to do is show that I'm not inferior to that device. And that becomes a much simpler path through. So that's 510K instead of de novo. So I think for us, it's not as heavy of a lift. We're expecting that we're going to be able to do that much more efficiently than we did with kidney. We'll get the samples in. We don't have formal guidance on this, but hopefully we got the samples that we need in in the first half, and that supports a submission maybe late second half next year.
Mike Matson
Analyst, Needham
Got it. And then just on the beta site and galactic registry, kind of near-term revenue opportunities, is there any way you can kind of frame that out or quantify what that could actually amount to in terms of revenue over the next few quarters until we get the kidney test launched?
Josh Riggs
President and CEO
Yeah, thanks. You know, I don't expect that it's going to be Thank you very much.
Mike Matson
Analyst, Needham
I understand if you can't comment on this, but you did announce a capital raise. So just curious, you know, why now and any comments there. But if you're not able to respond to that, I understand. Thanks.
Andrea James
Chief Financial Officer
Yeah, thank you so much. There is a Procept that's filed and we have to refer you to that and direct the questions to the filing. Sorry, Mike, our hands are tied there. But I will say one of the things that we hope that people see on this call, and there's a new earnings deck that's live online. It talks about our pipeline. It talks about seven centers are validating. It talks about we have line of sight getting through the FDA and so why we're excited about 2027. And that's what the focus of the call is today.
Gabby
Call Moderator
Thank you, Mike. We have Ben Mee from Stevens.
Ben Mee
Analyst, Stephens
Hi. Good afternoon. Thanks for taking the questions. This is Ben on for Mason Carrico. I appreciated the color you guys gave sort of where the centers stand in their validation activities. I was hoping you could expand a little bit on what that process looks like as they're moving into reimbursement and the reimbursement question is that next step both for Medicare and any commercial payers as well.
Josh Riggs
President and CEO
Yeah, so we can't, just because it's an RUO product, we can't support them in that process. This is something they have to do on their own under kind of CLIA rules. And so in that context, it looks a lot like what we went through as a CLIA lab. We had to show that there was analytical validation. We had to show that the test was clinically valid in the intended use population. And then we had to submit to MoldyX for reimbursement under the LCD. And so we would expect that anybody who's in a Moldy X jurisdiction would be following exactly the same process. And there are several labs that have been successful getting reimbursement through that exact process. Outside of Moldy X, it looks a little bit different. A lab that's maybe in First Coast would have to go to their MAC to try and either get on a case-by-case basis or get medical policy written One thing that we do influence, once there's a PLA code in place for our test, that does influence what MACs that are outside of Moldex pay once they write medical policy. And so that's supposed to go into effect. I'm looking at Andrea. I think early January, the PLA code goes into effect.
Andrea James
Chief Financial Officer
We hope to have a nationwide price in January of 2028. We are working on ways to bring that in and do that sooner by porting over to another reimbursed test, but that is TBD. But we hope to have a nationwide code starting 2028. Just to zero in on that, we just did strategic planning for next year, Josh. A huge part of what we were focused on is going after those initial centers in the Moldex jurisdictions. There is a lot of work that we can do where there's reimbursement. So I don't know if, Josh, you want to talk about going after those initial centers and what we're doing to kind of get ready for launch.
Josh Riggs
President and CEO
Sure. Yeah, I mean, that part's pretty straightforward. There's 67 centers or so that do greater than 50 kidney transplants a year inside the MULTI-X jurisdiction. For them, it's plug and play. Once we have an authorized product, they'll be able to, you know, we'll port over the reimbursement rate and then they can plug in the instrument and basically a week later, they're off to the races. We'll be focused on those labs in the initial launch phase while we work on market expansion in the other MACs and getting medical policy there.
Andrea James
Chief Financial Officer
It is a very highly concentrated market and there's lots of great customers we can go after while we wait for that nationwide reimbursement.
Ben Mee
Analyst, Stephens
Sounds good. Thank you for all that detail there. And then could you just give us an update on Europe? Have you submitted the necessary applications there? And just how should we think about the timing to commercialization there?
Josh Riggs
President and CEO
Thanks. Yeah, we're still looking kind of right here at the end of year or early part of January doing the IVDR submission. That will be both for kidney and for heart. And then the review time on that looks like about six months right now. Obviously, we don't control Suv2 anymore than we control the FDA. But, you know, that's the guidance that they're giving us. So that would put us with clearance mid-year. We know that ESOT is working on an update to guidelines for how these tests should be used. Many of the writers and the folks that are engaged in that process are using our technology in some form or fashion. So we feel good that there's push from the clinical community in Europe, but right now there's really no broad response. Reimbursement. There's maybe two or three countries that have found a way to pay for it, which is really, really limiting our ability to commercialize at this time.
Andrea James
Chief Financial Officer
Esot is European Society for Organ Transplantation. And just a quick commentary to understand the European market where you have more single payer systems. We expect the reimbursement to be lower than in the United States. But as a kitted product company, that's actually very advantageous to us because it makes it hard to operate an LDT product. More of that reimbursement will just be passed through to us. Whereas in the United States, there's more of a profit motive. The customers would buy our kit, here it is, and then they would bill at a higher rate. If there's lower reimbursement internationally, it would pass through to us. Kit is actually how you go after the European market. Even if you start to see reimbursement come through, don't be alarmed if it's lower than the US. It gets passed over to us for our kit.
Ben Mee
Analyst, Stephens
Got it. That makes sense. I appreciate you taking the questions today. I think I'll just keep it to two here.
Gabby
Call Moderator
Thank you, Ben. Do we have any additional questions? All right, Josh, turn it back over to you.
Josh Riggs
President and CEO
Thank you everybody for attending the call. Thank you for the thoughtful questions. I think we're very excited to be in the final steps here on a process that we started about three years ago. Really looking forward to having Graft Assured DX on market here in the United States and making it a lot easier for transplant centers to manage their patients locally. Appreciate you guys and thank you.